Pairidex Secures $4.9 Million in Latest Seed Funding Round

Pairidex secured $4.9 million in its latest Seed, adding another data point to the Unclassified funding market.

Pairidex Raises $4.9 million in Funding

RevaTerra® Closes Oversubscribed $1.265 Million Seed Financing Led by BlueLake.vc, a Deep Tech Venture Capital Firm Distributed by EIN Presswire Financing supports commercial scale-up of RevaTerra’s high-performance bioenergy technology across existing industrial infrastructure. FusionMRD™ is now commercially available as a laboratory-developed test (LDT) in Pairidex’s CAP accredited/CLIA certified lab.

Investors Behind the Funding

The round was backed by BlueLake. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Pairidex operates in Unclassified. Pairidex's financing adds to recent private-market activity.

Strategic Use of Funds

Support the Launch of New Highly Sensitive MRD Test for Leukemia.

Looking Ahead

This financing marks an important milestone for RevaTerra as we move from technical validation into commercial execution,

Source reference: original announcement/article.